Learn more about TABRECTA
For US residents only.
Testing and Diagnosis
METex14 in Metastatic Non-Small Cell Lung Cancer
How do you test for METex14?
METex14 can be detected by an FDA-approved comprehensive biomarker test. If you’re currently taking TABRECTATM (capmatinib) tablets, your doctor ran a comprehensive biomarker test and your tumor tested positive for METex14. If you haven’t been tested for METex14, learn how comprehensive biomarker testing can help inform your treatment options.
What is biomarker testing?
Biomarker testing can help you find out more about your type of lung cancer. This kind of test looks for specific noninherited gene mutations in your DNA that have been linked to cancer growth.
Comprehensive biomarker tests look for multiple genetic mutations that may be found in your type of cancer in one test, including mutations that lead to METex14.
Many cancer organizations encourage patients with advanced-stage cancer to ask their doctors about comprehensive biomarker testing.
If you’ve already had tumor tissue removed during biopsy or surgery, the tissue may be used for this test.
The results of your test can help you and your doctor find a treatment that is specific for your type of cancer. Ask your doctor about taking a comprehensive biomarker test.